Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The investigators' hypothesis is that therapy with Colesevelam, reduces fecal bile acid
excretion in patients with Irritable Bowel Syndrome (IBS)-diarrhea with prior evidence of
increased fecal 48 hour total bile acid excretion. The investigators aim to study the ability
of the HPLC assay for fecal bile acids to demonstrate responsiveness after treatment with
Colesevelam.
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)